Related references
Note: Only part of the references are listed.Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
George D. Wilson et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling
Diego A. Pedroza et al.
BRITISH JOURNAL OF CANCER (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
PI3K isoforms in cell signalling and vesicle trafficking
Benoit Bilanges et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
Yu-Hsuan Chen et al.
CANCERS (2019)
Molecular logic of mTORC1 signalling as a metabolic rheostat
Alexander J. Valvezan et al.
NATURE METABOLISM (2019)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
Cryo-EM structure of human mTOR complex 2
Xizi Chen et al.
CELL RESEARCH (2018)
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Yu-Ru Lee et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
An overview of rapamycin: from discovery to future perspectives
Young Ji Yoo et al.
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY (2017)
Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation
Hidetoshi Chibana et al.
HEART AND VESSELS (2017)
Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Vivek Narayan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Influence of autophagy on the efficacy of radiotherapy
Shing Yau Tam et al.
RADIATION ONCOLOGY (2017)
mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation
Charles Sinclair et al.
SCIENCE (2017)
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
Jung Hee Park et al.
ONCOTARGET (2017)
Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
Xiao-dong Pan et al.
PLOS ONE (2017)
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)
Fabio Gelsomino et al.
CLINICAL COLORECTAL CANCER (2017)
Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS
Hui Huang et al.
BIOMETALS (2017)
The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I
Andreia Cristina de Melo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Regulation of mTORC1 by growth factors, energy status, amino acids and mechanical stimuli at a glance
Peter Bond
JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION (2016)
Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo
Lijun Wang et al.
TUMOR BIOLOGY (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule
Cholpon S. Djuzenova et al.
ONCOTARGET (2016)
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo
R. Bai et al.
NEOPLASMA (2016)
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
E. Deutsch et al.
ANNALS OF ONCOLOGY (2015)
Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo
Tong Yongxi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer
Yu-Hsuan Chen et al.
CANCER LETTERS (2015)
Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Andrew J. Leiker et al.
CLINICAL CANCER RESEARCH (2015)
Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
Lei Chang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
Hiroki Ushijima et al.
JOURNAL OF RADIATION RESEARCH (2015)
Combining radiation with autophagy inhibition enhances suppression of tumor growth and angiogenesis in esophageal cancer
Yongshun Chen et al.
MOLECULAR MEDICINE REPORTS (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer
Jeroen Buijsen et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
Tongxin Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
Xiaofang Xing et al.
ANTI-CANCER DRUGS (2014)
The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
Thomas J. Hayman et al.
CLINICAL CANCER RESEARCH (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
Integration of molecular targeted therapy with radiation in head and neck cancer
Yu Du et al.
PHARMACOLOGY & THERAPEUTICS (2014)
PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
L. Chang et al.
CELL DEATH & DISEASE (2014)
mTOR pathway in colorectal cancer: an update
Maria Giovanna Francipane et al.
ONCOTARGET (2014)
NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro
Wen-juan Wang et al.
ACTA PHARMACOLOGICA SINICA (2013)
NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3
Wenjie Zhu et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
mTOR in aging, metabolism, and cancer
Marion Cornu et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2013)
Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial
David Azria et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin
Rebecca A. Dumont et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Signal integration by mTORC1 coordinates nutrient input with biosynthetic output
Christian C. Dibble et al.
NATURE CELL BIOLOGY (2013)
Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
Vincent A. Potiron et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
Sebastian Kuger et al.
TRANSLATIONAL ONCOLOGY (2013)
mTOR inhibitors in cancer therapy
Yekaterina Y. Zaytseva et al.
CANCER LETTERS (2012)
Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
George J. Cerniglia et al.
MOLECULAR PHARMACOLOGY (2012)
Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
Arunkumar Anandharaj et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2011)
TORC1/2 Inhibition with Concurrent Radiation Controls Inflammatory Breast Cancer in a Preclinical Animal Model Through Selective Blockade of Translation
E. P. Connolly et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
NORTH CENTRAL CANCER TREATMENT GROUP PHASE I TRIAL N057K OF EVEROLIMUS (RAD001) AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Jann N. Sarkaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
mTORC1- and mTORC2-interacting Proteins Keep Their Multifunctional Partners Focused
Ismael Bracho-Valdes et al.
IUBMB LIFE (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Yesid Alvarado et al.
TARGETED ONCOLOGY (2011)
Updates of mTOR Inhibitors
Hongyu Zhou et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
Takeshi Kaizuka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway
B. Markova et al.
ONCOGENE (2010)
The mTOR Pathway is Frequently Activated in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
Andrew M. Bellizzi et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
R. Diaz et al.
BRITISH JOURNAL OF CANCER (2009)
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Ker Yu et al.
CANCER RESEARCH (2009)
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Oleksandr Ekshyyan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Common corruption of the mTOR signaling network in human tumors
S Menon et al.
ONCOGENE (2009)
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells
Hui-Fang Li et al.
RADIATION ONCOLOGY (2009)
Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
Kwang Woon Kim et al.
AUTOPHAGY (2008)
Class IPI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
Remko Prevo et al.
CANCER RESEARCH (2008)
Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
Qi Xue et al.
CANCER RESEARCH (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Temsirolimus, an inhibitor of mammalian target of rapamycin
Brian I. Rini
CLINICAL CANCER RESEARCH (2008)
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
Gary D. Kao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis
Sherry A. Weppler et al.
RADIOTHERAPY AND ONCOLOGY (2007)
SF1126, a novel integrin-targeting phosphatidylinositol-3 kinase inhibitor, has radiosensitizing and anti-tumor effects in glioma model systems
H. G. Shu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas
JL Nakamura et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
ERBB receptor tyrosine kinases and cellular radiation responses
RK Schmidt-Ullrich et al.
ONCOGENE (2003)
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3k using LY294002
AK Gupta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats
PR Eynott et al.
IMMUNOLOGY (2003)
Share Paper
